Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
August 13, 2020

● Positive data from the first interim analysis in the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer were presented at ASCO20; response rate in the VB-111 treatment arm was 58% or higher       ● Successful pre-planned second interim analysis in OVAL, with a positive Data...

August 12, 2020

TEL AVIV, Israel , Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) in...

August 03, 2020

TEL AVIV, Israel , Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

June 22, 2020

The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer TEL AVIV, Israel , June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today presented a late-breaking study showing that its proprietary MOSPD2...

June 04, 2020

TEL AVIV, Israel , June 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis (RA). VBL's study entitled “MOSPD2: A novel therapeutic target...

June 01, 2020

OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control....

May 18, 2020

New data provide proof-of-concept for VBL's proprietary MOSPD2 bi-specific antibodies, observing survival benefit and no evidence of toxicity in a model of metastatic human cervical cancer TEL AVIV, Israel , May 18, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) announced today that new...

May 14, 2020

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , May 14, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020 , and provided a corporate update. “We reached an important milestone in our...

May 13, 2020

Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings TEL AVIV, Israel , May 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company, at a purchase price...

May 12, 2020

TEL AVIV, Israel , May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced...

View all press releases »